Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

of metastatic HRPC in combination with full-dose docetaxel (Taxotere(R)) and prednisone. The Company continues to expect to fully enroll this trial by the end of 2007. The Company expects to present clinical data from the Phase 1 and Phase 2 HRPC trials at scientific meetings throughout 2008.

Phase 1 Oral Picoplatin Trial:

An oral formulation of picoplatin is being evaluated in an ongoing Phase 1 clinical trial in solid tumors. Poniard has completed the planned enrollment of the planned dose levels and has expanded the enrollment to include additional testing of various dose levels to provide additional data to support further development. This Phase 1 study compares the bioavailability, pharmacokinetics, pharmacodynamics and safety of picoplatin administered orally with picoplatin administered intravenously in patients with advanced solid tumor malignancies. The company plans to present data from the Phase 1 trial at scientific meetings in 2008.

Lazard Presentation and Webcast Information

Dr. McMahon will present at the Lazard Capital Markets Fourth Annual Healthcare Conference today at 9:30 a.m. Eastern Time at The New York Palace Hotel. A live audio webcast of the presentation will be available for 10 business days on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Picoplatin

Picoplatin is a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations. Picoplatin has an improved safety profile compared to existing platinum-based chemotherapeutics and was designed to overcome platinum resistance. Picoplatin has been evaluated in more than 750 patients and has demonstrated activity in multiple indications with no evidence of significant kidney, nerve toxicity and hearing loss. The Company is evaluating picoplatin in four dif
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... WASHINGTON , March 4, 2015  Vanda ... today announced top-line results of the Phase II ... and efficacy of tradipitant as a monotherapy in ... atopic dermatitis. Despite a highly significant and clinically ... from baseline, p<0.0001) as measured on a 100mm ...
(Date:3/4/2015)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" ... company in China, today announced its financial results for ... Fourth Quarter 2014 Financial Highlights , ... by 36.2%, or 36.8% excluding the impact of foreign ... million in the same quarter of 2013. , ...
(Date:3/4/2015)... 4, 2015 GSI Group Inc. (NASDAQ: ... global leader and supplier of precision photonics and motion ... advanced industrial technology markets, today reported financial results for ... noted, all financial results in this press release are ... QuarterDuring the fourth quarter of 2014, GSI generated revenue ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9
... Reports Significant Progress in Advancing Second-Generation ... CCR9 ... ChemoCentryx, Inc.,today announced the completion of enrollment of 436 patients ... disease Trial), a Phase II/III clinical trial of Traficet-EN(TM),(CCX282-B) in ...
... through three years of LymphoStat-B ... infections or laboratory ... abnormalities over time -, ROCKVILLE, Md., June ... the presentation of results,from a long- term Phase 2 continuation trial ...
Cached Medicine Technology:ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 2ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 3ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 4ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 5ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohn's Disease 6Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports Positive Long-Term Data for LymphoStat-B in Patients With Active Systemic Lupus Erythematosus 7
(Date:3/5/2015)... Developers and plugin specialists of ... new transition pack entitled TranSlice Wipe for FCPX. , ... with ease while maintaining a professional look,” Said Christina ... a time saver with transitions our users will love.” ... split screen transitions with a new style. TranSlice Wipe ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Aureus Medical ... including locum tenens and direct hire physician jobs, has ... the Nebraska Academy of Family Physicians 67th Annual Meeting ... in La Vista, Nebraska. , The Annual Meeting ... to learn, networking opportunities, and an exhibition of products ...
(Date:3/5/2015)... Yorba Linda, CA (PRWEB) March 05, 2015 ... Professor of Neuroscience, Professor of Psychiatry and Psychology ... a keynote presentation at the upcoming BioConference Live ... in neuroscience. , The webcast , ... Schizophrenia and Depression,” is scheduled for Thursday, March ...
(Date:3/5/2015)... 2015 The pleasing melodies of live bluegrass ... of America bicycle and hand cycle ride as they arrive ... Flower Hill String Band will present a free concert ... from the Pentagon in Arlington, Virginia. , “We are thrilled ... “These folk have sacrificed so much. We love being to ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Afterglow®, ... light wave technology has just been rated #1 ... Than A Boyfriend.” Developed by urogynecologist Dr. Ralph ... higher levels of arousal by themselves and with ... near-IR light technology to enhance a women's sensual ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Released TranSlice Wipe Exclusively for Final Cut Pro X Editors 2Health News:Healthcare Staffing Agency, Aureus Medical Group, to Exhibit at the Nebraska Academy of Family Physicians Annual Meeting & Scientific Assembly 2Health News:Anthony Grace, MD, PhD, to Deliver Keynote at BioConference Live Neuroscience 2015 2Health News:Anthony Grace, MD, PhD, to Deliver Keynote at BioConference Live Neuroscience 2015 3Health News:Flower Hill String Band to Welcome Face of America with Bluegrass Music 2Health News:Flower Hill String Band to Welcome Face of America with Bluegrass Music 3Health News:Doctor’s Afterglow® Vibrator Enhances Women’s Arousal Using Light Waves, Ranks #1 In "Sex Toys That Are Better Than A Boyfriend" 2
... Day of Fall, September 22, Focuses on Preventing ... Today Congress issued,another call to action urging government, ... prevent the increasing number of falls,among people 65 ... (D-MD),and Mike Enzi (R-WY), as well as Representatives ...
... the 2006 Medicare Current Beneficiary Survey, WASHINGTON, ... option for low and moderate income seniors and ... data from the Medicare,Current Beneficiary Survey (MCBS)., ... and those,living in rural areas, rely on Medigap ...
... Olympic Games Champion Nikki Stone and Chronic Pain ... 22 The American Society of Pain,Educators (ASPE) ... Is Your Persistent Chronic Pain Weighing You Down? ... of proper,weight control in managing chronic pain., ...
... therapy delivered in only a week , , MONDAY, Sept. ... radiosurgery may be a viable treatment for recurring pancreatic ... Center, using their precise CyberKnife to perform radiosurgery, had ... the date of treatment. The range of survival was ...
... babies. , Now, it appears how infants respond to stress ... certain gene, according to a new study from the University of ... say they have also found that good parenting as early ... counter the effect the gene has in babies who initially do ...
... Enables SPECT Procedures ... New ASNC Technology Standards, POWAY, Calif., Sept. 22 ... imaging systems and,services to physicians, offices, hospitals and other medical ... Drug,Administration (FDA) 510(k) clearance for its new nSPEED(R) reconstruction,software -- ...
Cached Medicine News:Health News:Home Safety Council(R) Applauds Creation of Falls Prevention Awareness Day 2Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 2Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 3Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 4Health News:New Webcast Going for Gold to Educate on Importance of Healthy Diet In Persistent Chronic Pain Management 5Health News:Radiosurgery Proves Viable for Some Pancreatic Cancers 2Health News:UNC study: Parenting can override effect of genes in how babies respond to stress 2Health News:Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation 2Health News:Digirad Corporation Receives FDA 510(k) Clearance for nSPEED(R) Reconstruction Software for Improved Image Quality in Less Time With Less Radiation 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: